logo
  

Corteva, Inc. Q1 Profit Decreases, but beats estimates

Corteva, Inc. (CTVA) announced a profit for first quarter that decreased from last year but beat the Street estimates.

The company's bottom line totaled $419 million, or $0.60 per share. This compares with $595 million, or $0.83 per share, in last year's first quarter.

Excluding items, Corteva, Inc. reported adjusted earnings of $625 million or $0.89 per share for the period.

Analysts on average had expected the company to earn $0.84 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 8.0% to $4.49 billion from $4.88 billion last year.

Corteva, Inc. earnings at a glance (GAAP) :

-Earnings (Q1): $419 Mln. vs. $595 Mln. last year.
-EPS (Q1): $0.60 vs. $0.83 last year.
-Revenue (Q1): $4.49 Bln vs. $4.88 Bln last year.

-Guidance:
Full year EPS guidance: $2.70 to $2.90

For comments and feedback contact: editorial@rttnews.com

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT